Microbix Biosystms (TSE:MBX) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Microbix Biosystems Inc. has achieved record revenues of $25.4 million for fiscal year 2024, driven by a 42% increase in sales of its Antigens and QAPs products. The company reports a net income of $3.5 million, highlighting its successful growth and optimistic future outlook in the diagnostic-test market.
For further insights into TSE:MBX stock, check out TipRanks’ Stock Analysis page.
